Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−18.6333 USD
−20.29 M USD
0.00 USD
8.94 M
About Windtree Therapeutics, Inc.
Sector
CEO
Jed Andrew Latkin
Headquarters
Warrington
Website
Founded
1992
FIGI
BBG000JMNPX3
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of WINT is 0.3202 USD — it has decreased by −1.54% in the past 24 hours. Watch Windtree Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Windtree Therapeutics, Inc. stocks are traded under the ticker WINT.
WINT stock has fallen by −9.40% compared to the previous week, the month change is a −31.91% fall, over the last year Windtree Therapeutics, Inc. has showed a −97.58% decrease.
WINT reached its all-time high on Mar 1, 1996 with the price of 178,605,000.0000 USD, and its all-time low was 0.3300 USD and was reached on Dec 12, 2024. View more price dynamics on WINT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
WINT stock is 7.56% volatile and has beta coefficient of 1.15. Track Windtree Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Windtree Therapeutics, Inc. there?
Today Windtree Therapeutics, Inc. has the market capitalization of 2.88 M, it has increased by 7.95% over the last week.
Yes, you can track Windtree Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Windtree Therapeutics, Inc. is going to release the next earnings report on Apr 2, 2025. Keep track of upcoming events with our Earnings Calendar.
WINT earnings for the last quarter are −4.23 USD per share, whereas the estimation was −2.27 USD resulting in a −86.34% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Windtree Therapeutics, Inc. earnings.
Windtree Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
WINT net income for the last quarter is −2.75 M USD, while the quarter before that showed −12.02 M USD of net income which accounts for 77.14% change. Track more Windtree Therapeutics, Inc. financial stats to get the full picture.
No, WINT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 15.00 employees. See our rating of the largest employees — is Windtree Therapeutics, Inc. on this list?
Like other stocks, WINT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Windtree Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Windtree Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Windtree Therapeutics, Inc. stock shows the sell signal. See more of Windtree Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.